Medpark Company | Kossel Medtech Secures Multiple Certifications and Recognitions, Files IPO Prospectus

Recently

Medpark Park Enterprises

Kossel Medtech

Good news keeps coming, one success after another!

Kossel Medtech's "Octoparms" Trademark Officially Recognized as "Highly Renowned Trademark in Jiangsu Province"

Cathrough™ Transseptal Puncture Kit Approved for Class III Medical Device Registration Certificate.

Registration Certificate No.: China Medical Device Registration Approval 20243030479

MiSatin® Hydrophilic Coated Guidewire Approved for Class III Medical Device Registration Certificate.

Registration Certificate No.: China Medical Device Registration Approval 20243030296

Cathlink™ Electrode Lead Introducer Sheath Set Approved for Class II Innovative Medical Device Registration Certificate.

Registration Certificate No.: Su Medical Device Registration Approval 20242030151

Falexpand® Peripheral High-Pressure Balloon Dilatation Catheter has been approved by the National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA), and has now also received approval from Brazil's ANVISA.

Kossel Medtech (Suzhou) Co., Ltd

Kossel Medtech (Suzhou) Co., Ltd. was established in November 2013 and is located in Suzhou Science and Technology City, China. It is a platform enterprise with comprehensive R&D and production capabilities for vascular interventional medical devices, dedicated to providing systematic solutions for clinical use.

Kossel Medtech has established multiple business sectors. The parent company focuses on building a one-stop treatment system in the peripheral intervention field, with its first innovative product, the umbrella-shaped long-term caval filter Octoparms@, already approved for marketing. Its subsidiary Haiyu Xincheng is dedicated to the electrophysiology field, offering comprehensive solutions for treating tachyarrhythmia. Another subsidiary, Mixin Medtech, concentrates on the development of products in the coronary intervention field as well as the localization of overseas products and technologies. Meanwhile, subsidiary Haiwang Medtech is committed to the research and development of core raw materials that address critical technological bottlenecks.